BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tönshoff B, Momper R, Kühl PG, Schweer H, Schärer K, Seyberth HW. Increased thromboxane biosynthesis in childhood hemolytic uremic syndrome. Kidney International 1990;37:1134-41. [DOI: 10.1038/ki.1990.96] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Schmid DI, Kohan DE. Effect of shigatoxin-1 on arachidonic acid release by human glomerular epithelial cells11See Editorial by Kaplan, Myers, and Leonard, p. 1199. Kidney International 2001;60:1026-36. [DOI: 10.1046/j.1523-1755.2001.0600031026.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
2 Robson WL, Leung AK, Kaplan BS. Hemolytic-uremic syndrome. Curr Probl Pediatr 1993;23:16-33. [PMID: 8453889 DOI: 10.1016/0045-9380(93)90027-a] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
3 Karch H. Control of enterohaemorrhagicEscherichia coli infection: The need for a network involving microbiological laboratories and clinical and public health institutions. Eur J Clin Microbiol Infect Dis 1996;15:276-80. [DOI: 10.1007/bf01695657] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
4 Robson WL. Haemolytic uraemic syndrome. Paediatr Drugs 2000;2:243-52. [PMID: 10946413 DOI: 10.2165/00128072-200002040-00001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
5 Taylor CM, Lote CJ. Prostacyclin in diarrhoea-associated haemolytic uraemic syndrome. Pediatr Nephrol 1993;7:515-9. [DOI: 10.1007/bf00852530] [Cited by in Crossref: 4] [Article Influence: 0.1] [Reference Citation Analysis]
6 van de Kar N, Monnens L. 15 The haemolytic-uraemic syndrome in childhood. Baillière's Clinical Haematology 1998;11:497-507. [DOI: 10.1016/s0950-3536(98)80063-2] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
7 Leonhardt A, Busch C, Schweer H, Seyberth H. Reference intervals and developmental changes in urinary prostanoid excretion in healthy newborns, infants and children. Acta Paediatrica 1992;81:191-6. [DOI: 10.1111/j.1651-2227.1992.tb12202.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 0.6] [Reference Citation Analysis]
8 Leyva-Illades D, Cherla RP, Galindo CL, Chopra AK, Tesh VL. Global transcriptional response of macrophage-like THP-1 cells to Shiga toxin type 1. Infect Immun 2010;78:2454-65. [PMID: 20351145 DOI: 10.1128/IAI.01341-09] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
9 Proulx F, Seidman EG, Karpman D. Pathogenesis of Shiga Toxin-Associated Hemolytic Uremic Syndrome. Pediatr Res 2001;50:163-71. [DOI: 10.1203/00006450-200108000-00002] [Cited by in Crossref: 139] [Cited by in F6Publishing: 126] [Article Influence: 6.6] [Reference Citation Analysis]
10 Siegler RL. The Hemolytic Uremic Syndrome. Pediatric Clinics of North America 1995;42:1505-29. [DOI: 10.1016/s0031-3955(16)40096-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
11 Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, Kongkhum S, Heatherly D, Obrig T, Gear AR. Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function. Infect Immun 2005;73:8306-16. [PMID: 16299328 DOI: 10.1128/IAI.73.12.8306-8316.2005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
12 Young BA, Marsh CL, Alpers CE, Davis CL. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis. 1996;28:561-571. [PMID: 8840947 DOI: 10.1016/s0272-6386(96)90468-0] [Cited by in Crossref: 75] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
13 Hillyer CD, Duncan A, Ledford M, Barrett TJ, Klumpp SA, Anderson DC, McClure HM, Winton EF. Chemotherapy-induced hemolytic uremic syndrome: description of a potential animal model. J Med Primatol. 1995;24:68-73. [PMID: 8613975 DOI: 10.1111/j.1600-0684.1995.tb00148.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
14 Benigni A, Remuzzi G. The role of eicosanoids in the pathogenesis of hemolytic uremic syndrome. Prostaglandins, Leukotrienes and Essential Fatty Acids 1994;51:75-9. [DOI: 10.1016/0952-3278(94)90081-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
15 Betzen C, Plotnicki K, Fathalizadeh F, Pappan K, Fleming T, Bielaszewska M, Karch H, Tönshoff B, Rafat N. Shiga Toxin 2a-Induced Endothelial Injury in Hemolytic Uremic Syndrome: A Metabolomic Analysis. J Infect Dis 2016;213:1031-40. [PMID: 26582960 DOI: 10.1093/infdis/jiv540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
16 Seyberth HW, Leonhardt A, T�nshoff B, Gordjani N. Prostanoids in paediatric kidney diseases. Pediatr Nephrol 1991;5:639-49. [DOI: 10.1007/bf00856660] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
17 Dran GI, Fernández GC, Rubel CJ, Bermejo E, Gomez S, Meiss R, Isturiz MA, Palermo MS. Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Kidney Int 2002;62:1338-48. [PMID: 12234304 DOI: 10.1111/j.1523-1755.2002.kid554.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]